Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly.
Cecilia SgadariBiancamaria ScoppioOrietta PicconiAntonella TripicianoFrancesca Maria GaianiVittorio FrancavillaAngela ArancioMassimo CampagnaClelia PalladinoSonia MorettiPaolo MoniniLucia BrambillaBarbara EnsoliPublished in: Cancer research communications (2024)
This phase-2 trial showed that the HIV protease inhibitor indinavir may boost and extend the duration of the effects of chemotherapy in elderly with advanced progressive classic Kaposi sarcoma, without additional toxicity. Further, the amelioration of the immune status seen in responders suggests a better control of HHV-8 infection and tumor-cell killing. Thus, indinavir combined with chemotherapy may represent an important tool for the clinical management of classic Kaposi sarcoma in elderly patients.
Keyphrases
- antiretroviral therapy
- hiv positive
- locally advanced
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- men who have sex with men
- middle aged
- multiple sclerosis
- single cell
- oxidative stress
- community dwelling
- randomized controlled trial
- chemotherapy induced
- squamous cell carcinoma
- rectal cancer
- clinical trial
- radiation therapy
- mesenchymal stem cells
- bone marrow
- combination therapy
- study protocol
- smoking cessation